Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.14111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem?
Curr Opin Infect Dis
September 2025
Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Purpose Of Review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. This review summarizes current knowledge on the optimal use of SUL-DUR, whether administered alone or in combination with carbapenems, particularly imipenem.
Recent Findings: Data from registrational trial demonstrate that SUL-DUR is an effective and well tolerated treatment option for CRAB severe infections.
Re-do VATS for recurrent pneumothorax in a Birt-Hogg-Dubé syndrome patient.
Multimed Man Cardiothorac Surg
September 2025
Institute of Chest Surgery, Medanta, Gurugram, India
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant inherited disorder caused by mutation in a tumour suppressor gene, FLCN, leading to skin tumours (fibrofolliculomas), renal tumours and pulmonary cysts. Lung involvement is predominantly observed in 70% of the cases of BHDS, manifesting in the form of recurrent primary spontaneous pneumothorax. This video tutorial showcases the surgical management of recurrent right primary spontaneous pneumothorax in a young adult with a history of multiple episodes of bilateral pneumothorax managed by surgical intervention previously.
View Article and Find Full Text PDFMulti drug resistant Pseudomonas aeruginosa in burn infection among Iraq patients.
Cell Mol Biol (Noisy-le-grand)
September 2025
Medical Microbiology Department, College of Medicine, Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq.
Pseudomonas aeruginosa is a prominent opportunistic pathogen, especially in burn wound infections, and is often associated with high morbidity and mortality due to its multidrug resistance (MDR) characteristics.This study aimed to evaluate the multidrug resistance profile and perform a molecular phylogenetic analysis of P. aeruginosa isolates recovered from human burn infection sample .
View Article and Find Full Text PDFDesign of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFLong-term outcomes of corneal patch grafts.
Cell Tissue Bank
September 2025
Medline Hospital, Adana, Turkey.
To evaluate long‑term outcomes of corneal patch grafting (CPG) and to determine prognostic factors for anatomical and functional success. This retrospective study included 35 eyes from 35 patients who underwent CPG between April 2016 and September 2022 at Adana City Training and Research Hospital. Collected data included age, sex, preoperative and postoperative best-corrected visual acuity (BCVA), graft localization and size, anterior segment findings, graft survival, secondary surgical procedures, and rates of anatomical and functional success.
View Article and Find Full Text PDF